Chih-Cheng Lai to Betacoronavirus
This is a "connection" page, showing publications Chih-Cheng Lai has written about Betacoronavirus.
Connection Strength
0.133
-
Extra-respiratory manifestations of COVID-19. Int J Antimicrob Agents. 2020 Aug; 56(2):106024.
Score: 0.037
-
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020 Mar; 55(3):105924.
Score: 0.037
-
The COVID-19 pandemic and tuberculosis in Taiwan. J Infect. 2020 08; 81(2):e159-e161.
Score: 0.009
-
Co-infections among patients with COVID-19: The need for combination therapy with non-anti-SARS-CoV-2 agents? J Microbiol Immunol Infect. 2020 Aug; 53(4):505-512.
Score: 0.009
-
Global coronavirus disease 2019: What has daily cumulative index taught us? Int J Antimicrob Agents. 2020 Jun; 55(6):106001.
Score: 0.009
-
COVID-19 in long-term care facilities: An upcoming threat that cannot be ignored. J Microbiol Immunol Infect. 2020 Jun; 53(3):444-446.
Score: 0.009
-
Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020 Apr; 55(4):105946.
Score: 0.009
-
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020 Jun; 53(3):404-412.
Score: 0.009
-
Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020 Sep; 56(3):106103.
Score: 0.002